ライフサイエンスコーパス: dose reduction

1 Low-dose CT enabled significant radiation dose reduction.

2 (68%) received ibrutinib as planned without dose reduction.

3 treatment prematurely and the third required dose reduction.

4 s could continue cetuximab treatment without dose reduction.

5 c reference level is recommended for further dose reduction.

6 Nine patients required dose reduction.

7 ients (93%) achieved TCs of 3-7 mug/mL after dose reduction.

8 an 85% had worse survival than those without dose reduction.

9 and functional testing, as well as radiation dose reduction.

10 mong obese women was no longer apparent with dose reduction.

11 ged with bosutinib interruption and 32% with dose reduction.

12 study inception and all achieved successful dose reduction.

13 h selumetinib, with 37% requiring at least 1 dose reduction.

14 l can be managed successfully with temporary dose reduction.

15 ined as a reduction in the number of AAMs or dose reduction.

16 and quality of life may improve with opioid dose reduction.

17 urred because of excessive toxicity, despite dose reductions.

18 erate and did not require discontinuation or dose reductions.

19 time to simulate the corresponding relative dose reductions.

20 b-paclitaxel, with more frequent and earlier dose reductions.

21 ts, and 21% of patients required carfilzomib dose reductions.

22 This level of dose reduction (1/40th of a full dose) is unprecedented

23 13,392 patients with no renal indication for dose reduction, 13.3% were potentially underdosed.

24 mGy for the 120-kVp protocol, yielding a 27% dose reduction (25% and 75% percentiles: 23% and 37%, re

25 logical tolerance of ribavirin requiring its dose reduction (28%) and blood transfusion (15.7%) were

26 (72% v 55%; P = .0038), longer time to first dose reduction (3.7 v 1.5 months), and lower proportion

27 e 1,473 patients with a renal indication for dose reduction, 43.0% were potentially overdosed, which

28 Eleven patients (50%) required dose reduction, 7 because of rash.

29 Furthermore, PET/MR offered significant dose reduction (73%) compared with PET/CT.

30 cm +/- 39 for all reduced-dose CTs (average dose reduction, 88.2%).

31 blets, orally once daily for 12 weeks), with dose reduction according to estimated glomerular filtrat

32 discontinue LTOT and patient outcomes after dose reduction among adults prescribed LTOT for chronic

33 In conclusion, substantial dose reduction and daily administration of low doses of

34 uropathy is one of the most common causes of dose reduction and discontinuation of life-saving chemot

35 erse effects of cancer treatment, leading to dose reduction and discontinuation of life-saving chemot

36 Purpose To investigate a DLR algorithm's dose reduction and image quality improvement for pediatr

37 min plus insulin resulted in a daily insulin dose reduction and major glycemic control versus I-T1D.

38 of a hybrid CZT SPECT/64-slice CT system for dose reduction and to determine the maximal reduction po

39 Toxicities were managed by dose reduction and transfusions.

40 he majority are mild and can be managed with dose reduction and/or temporary suspension of medication

41 with 7.7% of patients requiring carfilzomib dose reductions and 19.2% discontinuing CRd due to adver

42 tis incidence and severity, and the need for dose reductions and interruptions of everolimus.

43 Toxicities were manageable with appropriate dose reductions and supportive care.

44 eptional responses can be achieved even with dose reductions and treatment breaks.

45 and diarrhea increased significantly in the dose-reduction and switch groups.

46 However, patients under agalsidase-beta dose-reduction and switch or a direct switch to agalsida

47 cial focus on renal outcome after 2 years of dose-reduction and/or switch to agalsidase-alpha.

48 linary pain programs, buprenorphine-assisted dose reduction, and behavioral interventions, were found

49 passing remission, oral glucocorticoid (OGC) dose reduction, and EGPA relapses.

50 astases is compromised with modest radiation dose reduction, and the use of iterative reconstructions

51 e 3 or 4 treatment-related toxic effects, no dose reductions, and no more than two antihypertensive d

52 s leading to death, drug discontinuation, or dose reduction; and select AEs.

53 Simulated radiation dose reduction applied to clinical CT angiography for fa

54 no dose reduction, normal-weight women with dose reduction (ARDI < 85%) experienced worse survival (

55 These dose reductions are done with exponential tapering progr

56 ring for hematologic toxicity (grade B) with dose reduction as needed.

57 Radiation dose reduction at pediatric CT was achieved when 40% ASI

58 Patients who met clinical criteria for dose reduction at randomisation (n=5356) had higher rate

59 or higher incidence of adverse event-related dose reductions at higher trough concentrations.

60 Dose reduction averaged 50% (P < .001).

61 Dose reductions because of adverse events were more freq

62 Fewer dose reductions because of toxicity were required in the

63 Dose reduction beyond this point resulted in overestimat

64 Many studies reported dose reduction, but rates of opioid discontinuation rang

65 With a radiation dose reduction by 2.36 mGy compared to standard of care

66 tal disease grading scale and corticosteroid dose reduction by at least 50%.

67 atient and to validate its use for potential dose reduction by using different image reconstruction a

68 ials aimed at estimating potential radiation dose reduction by using iterative reconstructions.

69 Conclusion A CT protocol with over 85% dose reduction can be used in patients with moderate to

70 Substantial radiation dose reductions can be achieved using targeted QI method

71 their response to therapy cessation and that dose reductions can help to prospectively infer differen

72 Furthermore, the d' showed that the dose-reduction capabilities differed between clinical im

73 mplex and the PLGA NPs, resulted in a 5-fold dose reduction compared to the CPX NS.

74 agnosis with the potential for a substantial dose reduction compared with PET/CT.

75 nterography with AIDR 3D allowed substantial dose reduction compared with that used with FBP CT enter

76 reconstruction may allow up to 59% radiation dose reduction compared with the dose with ASIR adaptive

77 erozygous for both, 100% required >/= 50% MP dose reduction, compared with only 7.7% of others.

78 carriers who were identified and received a dose reduction, compared with variant carriers who did n

79 in the BCR-ABL1 dynamics resulting from TKI dose reduction convey information about the patient-spec

80 % CI, 1.62-2.20) compared with those with no dose-reduction criteria (n = 13356).

81 Of the patients with 1 or no dose-reduction criteria assigned to receive the 5 mg twi

82 aban vs warfarin and the presence of 1 or no dose-reduction criteria were assessed.

83 s 5 mg twice daily; patients with at least 2 dose-reduction criteria-80 years or older, weight 60 kg

84 arfarin on major bleeding in patients with 1 dose-reduction criterion (HR, 0.68; 95% CI, 0.53-0.87) a

85 iterion (HR, 0.68; 95% CI, 0.53-0.87) and no dose-reduction criterion (HR, 0.72; 95% CI, 0.60-0.86) w

86 iterion (HR, 0.94; 95% CI, 0.66-1.32) and no dose-reduction criterion (HR, 0.77; 95% CI, 0.62-0.97) w

87 roke or systemic embolism in patients with 1 dose-reduction criterion (HR, 0.94; 95% CI, 0.66-1.32) a

88 Similar patterns were seen for each dose-reduction criterion and across the spectrum of age,

89 Little is known about patients with 1 dose-reduction criterion who received the 5 mg twice dai

90 us, and appropriate for patients with only 1 dose-reduction criterion.

91 ily dose of apixaban or warfarin, 3966 had 1 dose-reduction criterion; these patients had higher rate

92 ize should not be a major factor influencing dose reduction decisions in women with ovarian cancer.

93 Dose reduction decreased mean exposure by 29% (from 48.5

94 patients did not need dose adaptations, but dose reductions did not lead to an inferior survival.

95 Short-term outcome studies of antipsychotic dose-reduction/discontinuation strategies in patients wi

96 asthma undergoing an inhaled corticosteroid dose reduction do not support the use of vitamin D suppl

97 (8%) patients experiencing grade 3/4 events; dose reduction due to diarrhea occurred in 6% of affecte

98 Rates of discontinuation and dose reductions due to AEs were 17% and 10%, respectivel

99 19 (73%) patients required dose reductions due to drug-related adverse events.

100 ed on sorafenib treatment but required early dose reductions due to palmar plantar erythrodysesthesia

101 Two patients withdrew and 5 required IL-2 dose reductions due to side effects.

102 tated the contemporary practice of radiation dose reduction during abdominal CT examinations.

103 Eplerenone treatment led to a loop diuretic dose reduction during follow-up without evidence of trea

104 ime (2 definitions used), 50% or greater OGC dose reduction during weeks 48 to 52, or no EGPA relapse

105 Eight patients had dose reductions during therapy, and 7 patients discontin

106 of low-contrast detectability when radiation dose reductions exceed approximately 25%.

107 We report the dose reduction factor of 1.28 for BBT-059 (0.3 mg/kg) co

108 on in mice at single nontoxic oral dose by a dose-reduction factor of 1.28.

109 e basis of patient size, while the pediatric dose reduction factors of this study allow calculation o

110 Pediatric dose reduction factors were calculated on the basis of S

111 The fractions of adult doses (pediatric dose reduction factors) used within the consortium for p

112 The average relative dose reduction for abdominopelvic CT was 29% (4.8/6.8 mG

113 d erythropoietin, blood transfusions, or RBV dose reduction for anemia.

114 0% ASIR implementation, the average relative dose reduction for chest CT was 39% (2.7/4.4 mGy), with

115 the radiologic imaging dose range, rendering dose reduction for children unjustifiable and counterpro

116 The relatively modest effect may reflect 50% dose reduction for each allergen in the mixture.

117 icities were observed; two patients required dose reduction for grade 3 fatigue and rash.

118 nciclovir of 17 mg/kg/day, with a stratified dose reduction for impaired creatinine clearance, given

119 In this procedure, dose reduction for particular organs ranged between 49-8

120 Moreover, we estimated the potential for dose reduction for PET/MR compared with PET/CT consideri

121 standard dose of melphalan 200 mg/m(2), with dose reduction for severe kidney dysfunction.

122 o HIV-1 PrEP, leading to a possible fivefold dose reduction for some of the agents.

123 Dose reductions for adverse reactions were permitted for

124 s of intravenous regimens with proportionate dose reductions for toxicity.

125 A radiation dose reduction from 70 to 50 Gy (RBE) did not seem to in

126 steroids had a 50% or greater corticosteroid dose reduction from baseline.

127 f the 87 patients (94%), with the percentage dose reduction greater for CT angiography than for chest

128 about 3 ml/min per 1.73 m(2) (P=0.01) in the dose-reduction group, and the median albumin-to-creatini

129 8), receive a reduced dose of 0.3-0.5 mg/kg (dose-reduction group, n=29), or switch to 0.2 mg/kg agal

130 Dose reductions had to be performed in 3 of 13 patients

131 the DLR affects image quality and radiation dose reduction has yet to be fully investigated.

132 eing a safety concern, substantial ribavirin dose reductions have to be considered in these patients,

133 The mean radiation dose reductions (ie, radiation protection) provided by X

134 Despite a 60% dose reduction, images reconstructed with SAFIRE allowed

135 d to CT protocol modifications for radiation dose reduction, improved diagnostic performance for dete

136 technology resulted in incremental radiation dose reduction in a statewide coronary computed tomograp

137 iscontinuation (period 2), and after the RAL dose reduction in arm 2 (period 3).

138 As example applications, we demonstrate dose reduction in cryo-electron microscopy experiments,

139 Each regimen incorporated a 50% dose reduction in patients with clinical features known

140 se swallowed fluticasone propionate (FP) and dose reduction in patients with eosinophilic esophagitis

141 The mean doubling dose reduction in SPMCh PC(20) value was 0.50 and 0.27 w

142 LOBP was defined as a more than 1 doubling dose reduction in SPMCh PC(20) value.

143 More dose reduction in the isocentric region was observed in

144 30-50 mL/min, potentially due to unnecessary dose reduction in the setting of acute kidney injury (AK

145 and other adverse effects, and they advised dose reduction in women and in older adults.

146 AEs resulted in dose reductions in 17.2% of patients and drug discontinu

147 Adverse events resulted in linezolid dose reductions in 4, temporary interruptions in 5, and

148 ppetite, nausea, and fatigue and resulted in dose reductions in 79% and holds in 65% of patients.

149 Adverse events led to dose reductions in six (14%) patients and treatment disc

150 ffect at concentration of 1.3 muM, 11.7-fold dose reduction index and no toxicity toward host cells.

151 Our developed compounds exhibited >100-fold dose reduction index that results in complete resensitiz

152 Accordingly, cytotoxic chemotherapy dose reduction is common in patients with elevated BMI.

153 Conclusion: (68)Ga-PSMA-11 dose reduction is not feasible without a negative impact

154 A radiation dose reduction is possible for patients responding to IC

155 taining diagnostic image quality and whether dose reduction is related to body mass index (BMI).

156 This estimated dose reduction is somewhat smaller than that suggested b

157 e-beta dose had a stable disease course, but dose reduction led to worsening of renal function and sy

158 kg once every 3 weeks (n = 10), but frequent dose reductions led to testing of 2.4 mg/kg (n = 39) in

159 At moderate levels of dose reduction, lower-dose FBP images without ANLM or SA

160 e events that resolved spontaneously or with dose reduction (maximum tolerated dose 1800 mg bid).

161 e counts during peg-IFN/RBV therapy; peg-IFN dose reductions may be a consideration in patients with

162 e reduction or discontinuation, and this MMF dose reduction (MDR) can lead to rejection and possibly

163 death compared with those who did not have a dose reduction (n=15 749).

164 ompared with women with normal weight and no dose reduction, normal-weight women with dose reduction

165 The ease of administration coupled with the dose reduction observed in this study points to the Nano

166 Ease of administration coupled with dose reduction observed in this study suggests the Nanop

167 RBV dose reduction occurred in 25% without any treatment dis

168 occurred in 13% of patients, and umbralisib dose reductions occurred in 15% of patients.

169 Variant allele carriers received an initial dose reduction of >/= 50% followed by dose titration bas

170 reatment led to a mean furosemide equivalent dose reduction of -2.2 mg/day (-2.9 to -1.6) throughout

171 Results RD CT resulted in a mean dose reduction of 54% compared with SD.

172 .4 mSv for PET/MRI, resulting in a potential dose reduction of 79.6% (P < 0.001).

173 -1.4mSv in PET/MRI, resulting in a potential dose reduction of 79.6% (p<0.001).

174 MBIR allowed a dose reduction of 84% versus standard-dose ASIR 50% (mea

175 A reduced-dose protocol with MBIR allowed a dose reduction of 84% without increasing noise and witho

176 67%) in the study cohort achieved at least 1 dose reduction of any anti-diabetic medication.

177 e beta1 antibody, OS2966, allowing a 20-fold dose reduction of bevacizumab per cycle in this model.

178 The relationship between the dose reduction of BS/SC and some geometric parameters in

179 ad reactivation, required discontinuation or dose reduction of cancer treatment.

180 0/muL for at least 4 weeks, despite delay or dose reduction of chemotherapy.

181 ation of an essential amino acid could allow dose reduction of cisplatin; this could reduce the drug'

182 l line to the chemotherapeutic and >100-fold dose reduction of cytarabine in both AML cell lines and

183 A dose reduction of lenalidomide 5 mg per day was required

184 Dose reduction of non-vitamin K antagonist oral anticoag

185 Our results show that dose reduction of ototoxic agents is a safe, effective t

186 nts may benefit from the clinically relevant dose reduction of PET/MRI compared to PET/CT.

187 , revealing a synergistic effect of combined dose reduction of these proteins.

188 Discontinuation or dose reduction of voriconazole resulted in improvement o

189 We suggest that deferred renal dose reduction of wide therapeutic index antibiotics cou

190 he use of an AP projection allowed for total dose reductions of 16%, 15%, and 12% for lungs, breast,

191 For radiation dose reductions of 25% or more, the ability to resolve t

192 GL/HDL ratio </= 3 to determine success with dose reductions of anti-diabetic medications showed a se

193 ive screening tool to determine success with dose reductions of anti-diabetic medications.

194 the two TLR agonists allows for significant dose reductions of each component to achieve a level of

195 lymphoma (HL) is unclear, and the impact of dose reductions of these drugs on outcome and tolerabili

196 rting after de-escalation (drug cessation or dose reduction) of anti-TNF agents and/or immunomodulato

197 dies (18 on de-escalation [drug cessation or dose reduction] of immunomodulator monotherapy, 8 on imm

198 tial benefits of PET(DL) include a radiation dose reduction on follow-up scans and artifact removal i

199 eigh benefits, but evidence on the effect of dose reduction on patient outcomes has not been systemat

200 51) or placebo (n=5) to assess the effect of dose reduction on safety and immunogenicity.

201 The most common reasons for dose reduction or delays were nonhematologic.

202 research published in English that addressed dose reduction or discontinuation of LTOT for chronic pa

203 the only available treatment options involve dose reduction or discontinuation of therapy, which have

204 nevertheless, important because they prompt dose reduction or discontinuation of these life-saving m

205 late mofetil (MMF) side effects often prompt dose reduction or discontinuation, and this MMF dose red

206 ll count to 1.0 x 109/L or less leading to a dose reduction or drug withdrawal.

207 ct patients' quality of life and may lead to dose reduction or even cessation of anti-tumor therapy.

208 Rates of dose reduction or suspension attributable to AEs were al

209 nd-organ damage and clinical symptoms during dose reduction or switch to agalsidase-alfa.

210 upper limit of normal, which resolved after dose reduction or temporary interruption of lomitapide.

211 ticipants completed therapy without need for dose reduction or transfusion; eight required two or mor

212 eurotoxicity occurs frequently, necessitates dose reduction or treatment cessation, and affects funct

213 %, and the estimated cumulative incidence of dose reduction or treatment discontinuation because of t

214 ll lymphoma-emerged in combination with gene dose reduction or when challenged by chronic fur mite in

215 ated neutropenia commonly included antiviral dose reduction or withdrawal (51%).

216 d risk of relapse was high during medication dose reduction or withdrawal.

217 ured: 46% of patients' first DLTs and 88% of dose reductions or discontinuations of treatment because

218 gh common, were manageable, often leading to dose reductions or interruptions in treatment with linez

219 y hematological, which were resolved without dose reductions or interruptions.

220 including discontinuation of anticoagulants, dose reduction, or low-molecular-weight heparin replacem

221 om toxicity were evaluated, including delay, dose reduction, or termination of chemotherapy.

222 rvention previously demonstrated significant dose reduction over a period of one year.

223 Dose reduction owing to toxic effects occurred in 56% of

224 in a 28% reduction in drug cost from before dose reduction (P < .001).

225 which translated into an estimated radiation dose reduction potential (+/-95% confidence interval) of

226 onally, each metric was used to estimate the dose reduction potential of IR algorithms while maintain

227 FBP and SAFIRE and to estimate the radiation dose reduction potential of SAFIRE.

228 ttenuating liver lesions and to estimate the dose reduction potential of the IR algorithm in question

229 Radiation dose reduction potential ranged from 56% to 60% and from

230 dose in patients with a renal indication for dose reduction (potential overdosing) and use of a reduc

231 Dose reduction potentials based on both reading sessions

232 Despite the lower anti-FXa activity, dose reduction preserved the efficacy of edoxaban compar

233 Radiation dose reduction provided by the TCs was analyzed in 117 d

234 uced-dose images (generated from tube A; 60% dose reduction) reconstructed with sinogram-affirmed ite

235 A 50% dose reduction remained effective in 73%-93% of patients

236 Radiation dose reduction resulted in significantly improved swallo

237 rior LCR for vendors 1 and 2 for FBP and 25% dose reductions resulted in inferior and equivalent perf

238 Relative to FBP and full dose, 25%-50% dose reductions resulted in inferior LCR for vendors 1 a

239 t least low disease activity) is maintained, dose reduction should be attempted.

240 Dose reductions should be taken into account to minimize

241 safety outcomes with warfarin stratified by dose reduction status.

242 Dose reduction strategies are often used to avoid chemot

243 Dose-reduction strategies targeted to the highest quarti

244 hypothesis under controlled conditions, this dose-reduction study was performed using a standardized

245 assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy

246 -based eGFR revealed decreasing eGFRs in the dose-reduction-switch group and the switch group.

247 equent switch to 0.2 mg/kg agalsidase-alpha (dose-reduction-switch group, n=28), or to directly switc

248 r opinion, modern CT imaging with the use of dose reduction techniques and iterative reconstructions

249 emphysema and airway disease, evaluation of dose reduction techniques, and use of deep learning for

250 d tomography have caused various advances in dose reduction technologies.

251 n risk, particularly for young children, and dose reduction tends to result in reduced resolution.

252 of IR, which indicates less potential for IR dose reduction than previously thought.

253 DLR demonstrated 52% (1 of 2.1) greater dose reduction than SBIR.

254 ura Clarity system resulted in a significant dose reduction, thereby leading to a significant decreas

255 Dose reduction through adsorption to aluminium hydroxide

256 ing, tissue perfusion imaging, and radiation dose reduction through iterative reconstruction are expl

257 Forty percent of patients required erlotinib dose reduction to 100 mg per day and 16% to 50 mg per da

258 ed to warfarin or HDER (60 mg daily or a 50% dose reduction to 30 mg daily for CrCl 30-50 mL/min, bod

259 , is the process of medication withdrawal or dose reduction to correct or prevent medication-related

260 ts may allow study of mixed extracts without dose reduction to improve efficacy.

261 sfusions while on ruxolitinib or ruxolitinib dose reduction to less than 20 mg twice a day with at le

262 Dose reductions to 1.2 mg/kg were instituted as a result

263 ed treatment without adverse event requiring dose reduction (tolerability), and elevation of urate as

264 achieved when 40% ASIR was implemented as a dose reduction tool only; no net change to the magnitude

265 related, and resolved spontaneously or after dose reduction, use of antinausea drugs, or both.

266 th CT would potentially allow (18)F-fluoride dose reduction using hybrid (18)F-fluoride PET/MR imagin

267 40 studies examining patient outcomes after dose reduction (very low overall quality of evidence), i

268 The strongest predictor of dose reduction was a high BMI.

269 Lenalidomide dose reduction was associated with worse overall surviva

270 Dose reduction was determined by comparing size-specific

271 Mycophenolate mofetil dose reduction was independently associated with a subst

272 Dose reduction was needed in 2 patients and 2 others com

273 ntly reduced opioid dose over time, and this dose reduction was partially statistically mediated by c

274 Dose reduction was permitted for toxicity.

275 Dose reduction was required for a neutrophil count <0.75

276 Of patients with skin toxic effects, dose reduction was required for symptom management in 9

277 Peg-IFN or RBV dose reduction was required in 23% and 43% of patients,

278 Clinical management or dose reduction was required in a third of cases.

279 different, regardless of whether 50% or 75% dose reduction was used.

280 icular conduction system is affected by Tbx3 dose reduction, we first characterized electrophysiologi

281 ted breast computed tomography for radiation dose reduction, we propose a framework that combines 3D

282 djusted differences in comfort and radiation dose reductions were calculated by using a mixed logisti

283 re assessed over a 21-day cycle; thereafter, dose reductions were implemented as needed and patients

284 Dose reductions were made if recurrent grade 2 adverse e

285 Dose reductions were more common in patients receiving t

286 Dose reductions were more frequent with 5.5 mg dose.

287 2, and the events most frequently leading to dose reductions were rash and arthralgia or arthritis.

288 Brentuximab dose reductions were required in 38% of patients, most f

289 cases, there was a statistically significant dose reduction when the lower fluoroscopic pulse rate wa

290 scribed and generally easily manageable with dose reductions when indicated.

291 ns repeatedly required profound voriconazole dose reductions whenever high-dose meropenem was added.

292 Efforts towards further dose reduction which would permit replacing chest X-ray

293 ffective treatment for CIPN exists, short of dose-reduction which worsens cancer prognosis.

294 rs intensively try to find new solutions for dose reduction while maintaining a high diagnostic value

295 h FBP, ADMIRE allows a substantial radiation dose reduction while preserving low-contrast detectabili

296 Further potential for radiotracer dose reduction, while maintaining PET image quality (IQ)

297 r an adjunctive therapy to facilitate opioid dose reduction whilst delivering significant pain relief

298 ons, many strategies have been developed for dose reduction with CTA.

299 The DLR algorithm improved image quality and dose reduction without sacrificing noise texture and spa

300 disease may increase bleeding risk, whereas dose reductions without a firm indication may decrease t